All companies
Visit website
PLASMOLOGY4
OperatingPlasmology4, Inc.
Healthcare · Technology · Founded 2010
Revolutionary technology for healthcare
Post-money valuation ⓘ
$137.5M
As of Oct 2024 · from Plasmology4 Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$728,771
Across 1 round since 2024
Latest share price
$1.17
Plasmology4 Common Stock 1 offering price
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its source$0
−$10.4M
2022
$0
−$4.2M
2023
$0
−$7.0M
2024
$0
−$4.4M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$10,364,267
-$4,228,434
-$6,999,368
-$4,359,243
Taxes paid
$0
$0
$27
$56
Balance sheet
Cash
$1,171,233
$466,085
$16,676
$12,162,189
Accounts receivable
$0
$0
$0
$0
Total assets
$1,902,460
$1,250,330
$634,623
$12,483,429
Short-term debt
$4,758,917
$1,000,000
$1,492,220
$1,491,758
Long-term debt
$336,923
$0
$0
$276,151
Total liabilities
$5,095,840
$1,000,000
$1,492,220
$1,767,909
Other
Headcount
—
7
7
6
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$137.5M
post-money
Plasmology4 Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $728.8K / $1.2MInvestors 215Post-money $137.5M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 2 of 2 annual reports (FY2024–FY2025)
215 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 20 filings on EDGARSource: ManualCIK 0001488790Share price $1.17
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.